Mammotome boosts production of breast biopsy needles amid nationwide shortage

Mammotome ramps up production of its Revolve breast biopsy needles amid shortage caused by Hologic Brevera recall. FDA projects the shortage may last through early 2027; ACR encourages using alternatives to prevent delayed care.

• The shortage began after Hologic recalled its Brevera 9 Gauge Needles due to potential metallic particle contamination, risking foreign body reactions and repeat biopsies.
• Both Hologic and Mammotome are expanding production of alternative devices (Eviva and Revolve systems, respectively) to meet demand.
• Mammotome added manufacturing capacity and is working with suppliers to deliver reliable biopsy solutions without delaying breast cancer diagnoses.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.